Actively Recruiting
Effects of Paroxetine on Cardiovascular Function in Septic Patients
Led by Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude · Updated on 2025-01-06
92
Participants Needed
2
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It is known that septic shock is characterized by arterial hypotension, decreased peripheral vascular resistance and hyporeactivity to vasoconstrictor agents, with NO being an important mediator of this organ dysfunction. Data in the literature have shown that hyporeactivity to catecholamines is associated with a decrease in the density of α and ß receptors in the aorta and heart, respectively, as well as an increase in GRK2 levels and that NO contributes to the increase of this kinase in sepsis . Based on this, it is hypothesized that cardiac dysfunction and decreased peripheral vascular resistance observed in sepsis may result from an increase in GRK2 activity and/or expression and its inhibition may be a relevant therapeutic target in septic shock patients. Based on this line, a measurable clinical benefit of paroxetine through the regulation of GRK2 expression in patients with septic shock is postulated.
CONDITIONS
Official Title
Effects of Paroxetine on Cardiovascular Function in Septic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years of age
- Patient diagnosed with septic shock for less than 48 hours and using a minimum dose of noradrenaline (0.01 mcg/kg/min)
- Patients and/or legal guardians who consented to participate in the study through the free and informed consent term before randomization
You will not qualify if you...
- Pregnant women
- Patients with inability to use the gastrointestinal tract
- Patients with known intolerance to paroxetine and/or fluoxetine
- Patients on concomitant use of medications that may potentiate the occurrence of serotonin syndrome (tramadol, citalopram, escitalopram, sertraline, desvenlafaxine, venlafaxine, duloxetine, sibutramine, bupropion, amitriptyline, nortriptyline, lithium)
- Patients in end-of-life care or with an expected survival of less than 24 hours at the time of eligibility
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospital Maternidade São José de Colatina
Colatina, Espírito Santo, Brazil
Actively Recruiting
2
Hospital São José
Criciúma, Santa Catarina, Brazil, 88801460
Actively Recruiting
Research Team
F
felipe dal-pizzol, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here